Phase Ib/II Clinical Trial of Glembatumumab Vedotin and Nivolumab in Advanced Solid Tumors

Trial Profile

Phase Ib/II Clinical Trial of Glembatumumab Vedotin and Nivolumab in Advanced Solid Tumors

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 30 May 2018

At a glance

  • Drugs Glembatumumab vedotin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Advanced breast cancer; Solid tumours; Uveal melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Apr 2018 According to a Celldex Therapeutics media release, status changed from not yet recruiting to withdrawn prior to enrolment, because based on the data from METRIC study, company has decided to discontinue the glembatumumab vedotin program across all indications.
    • 06 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top